Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Chemotherapy + PBSCT in Metastatic TNBC
NCT02183805Phase 2Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2014
- Primary completion
- Dec 2020
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel, cyclophosphamide and carboplatin in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen University. Primary endpoint: Progression free Survival at 24 months. Started Jun 2014; status: terminated.
02
Drugs
nab-paclitaxelcyclophosphamidecarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02183805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183805.